NADAC acquisition cost data for CILOXAN 0.3% OINTMENT. This is a brand-name medication — generic alternatives may be available at lower prices.
| NDC | NADAC/Unit | Effective Date | Type |
|---|---|---|---|
| 00065065435 | $58.93 | 2021-06-23 | Rx |
| 00065065435 | $58.93 | 2021-06-23 | Rx |
| 00065065435 | $58.93 | 2021-06-23 | Rx |
| 00065065435 | $58.93 | 2021-06-23 | Rx |
| 00065065435 | $58.93 | 2021-06-23 | Rx |
| 00078084101 | $61.36 | 2022-07-27 | Rx |
| 00078084101 | $61.36 | 2022-07-27 | Rx |
| 00078084101 | $61.36 | 2022-07-27 | Rx |
| 00078084101 | $61.36 | 2022-07-27 | Rx |
| 00078084101 | $61.36 | 2022-07-27 | Rx |
Generic: Ciprofloxacin HCl | Manufacturer: Overall
| Year | Total Spending | Claims | Beneficiaries | Cost/Unit |
|---|---|---|---|---|
| 2019 | N/A | N/A | 5,360 | N/A |
| 2020 | N/A | N/A | 3,859 | N/A |
| 2021 | $445.5K | 1,796 | 3,357 | $63.77 |
| 2022 | $1.3M | 5,116 | 3,453 | $66.23 |
| 2023 | $1.5M | 5,169 | 3,611 | $74.96 |
| State | Total Cost | Claims | Beneficiaries |
|---|---|---|---|
| New York | $181.0K | 566 | 326 |
| Florida | $132.8K | 487 | 391 |
| Pennsylvania | $123.3K | 447 | 287 |
| Ohio | $103.5K | 347 | 231 |
| Texas | $99.2K | 373 | 292 |
| California | $98.9K | 364 | 295 |
| New Jersey | $54.7K | 204 | 154 |
| Massachusetts | $41.5K | 142 | 87 |
| North Carolina | $40.1K | 148 | 112 |
| Illinois | $39.8K | 148 | 112 |
| Georgia | $36.2K | 130 | 86 |
| Virginia | $33.6K | 126 | 82 |
| Arizona | $31.5K | 112 | 86 |
| Connecticut | $29.4K | 101 | 66 |
| Tennessee | $29.2K | 107 | 64 |
| Michigan | $26.9K | 100 | 88 |
| Maryland | $25.8K | 99 | 72 |
| Wisconsin | $25.8K | 93 | 52 |
| Missouri | $25.2K | 82 | 61 |
| Indiana | $24.8K | 89 | 65 |
| West Virginia | $23.7K | 60 | 34 |
| Washington | $22.1K | 80 | 44 |
| Louisiana | $19.9K | 76 | 49 |
| South Carolina | $17.8K | 67 | 43 |
| Kentucky | $17.0K | 64 | 58 |
| New Hampshire | $13.4K | 26 | 18 |
| Iowa | $12.8K | 46 | 33 |
| Mississippi | $11.6K | 42 | 33 |
| Colorado | $9.8K | 34 | 27 |
| Delaware | $8.5K | 33 | 12 |
| Hawaii | $8.4K | 32 | 19 |
| Alabama | $8.2K | 30 | 26 |
| Montana | $7.7K | 29 | N/A |
| Oregon | $6.6K | 25 | 19 |
| Maine | $6.4K | 22 | 19 |
| Kansas | $5.9K | 22 | 19 |
| Puerto Rico | $5.6K | 22 | N/A |
| Rhode Island | $5.6K | 20 | 15 |
| Oklahoma | $5.5K | 21 | 20 |
| Nebraska | $5.0K | 19 | 17 |
| Utah | $5.0K | 19 | 19 |
| New Mexico | $4.9K | 19 | 17 |
| Nevada | $4.7K | 18 | N/A |
| Minnesota | $4.5K | 15 | 13 |
| District of Columbia | $4.2K | 16 | N/A |
| Arkansas | $2.9K | 11 | 11 |
The DrugPricePeek editorial team aggregates and verifies drugs data from CMS NADAC & Medicare Part D. Every statistic on this site is cross-referenced against the official source before publication, with quarterly re-verification cycles.
Read our full methodology or contact us with corrections.
Explore More Data Tools
For adjacent public-data tools, methodology notes, and network updates, visit DataPeek Facts.